Privia Health (PRVA)
Market Price (11/6/2026): $23.95 | Market Cap: $3.1 BilSector: Health Care | Industry: Health Care Services
Privia Health (PRVA)
Market Price (11/6/2026): $23.95Market Cap: $3.1 BilSector: Health CareIndustry: Health Care Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13% Low stock price volatilityVol 12M is 33% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Health Data Analytics. | Weak multi-year price returns2Y Excs Rtn is -4.4%, 3Y Excs Rtn is -69% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 67x, P/EPrice/Earnings or Price/(Net Income) is 107x Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.2% Key risksPRVA key risks include [1] its operational reliance on key third-party vendors, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13% |
| Low stock price volatilityVol 12M is 33% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Health Data Analytics. |
| Weak multi-year price returns2Y Excs Rtn is -4.4%, 3Y Excs Rtn is -69% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 67x, P/EPrice/Earnings or Price/(Net Income) is 107x |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.2% |
| Key risksPRVA key risks include [1] its operational reliance on key third-party vendors, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Privia Health (PRVA) stock has remained largely at the same level since 7/31/2026 because of the following key factors:
1. Mixed Fiscal Q3 2026 Performance and Market Reaction.
Privia Health reported robust revenue for fiscal Q3 2026 (ended September 30, 2026), reaching $657.0 million, which surpassed analysts' consensus estimates of $611.3 million by 7.5%. The company also raised its full-year 2026 revenue guidance to between $2.50 billion and $2.55 billion. However, its Adjusted EPS of $0.21 missed analysts' consensus estimates of $0.24 by 11.8%. This mixed financial performance, particularly the Adjusted EPS miss, led to a 2% decline in the stock price immediately after the earnings release, tempering overall market enthusiasm despite strong revenue growth and an increased full-year outlook.
2. Unfavorable Market Response to Strong Fiscal Q2 2026 Earnings.
Despite a significant beat in fiscal Q2 2026 (ended June 30, 2026) results, Privia Health's stock experienced a notable decline. The company reported actual revenue of $632.63 million, exceeding analysts' expectations of $598.84 million by 5.64%. Additionally, Privia Health announced an EPS of $0.19, substantially topping analysts' consensus estimates of $0.07 by $0.12. Despite these strong financial results, the stock price was down by 8.18% in one day following the announcement, indicating that even positive company-specific news did not translate into sustained upward momentum during the period.
Show more
Privia Health (PRVA) stock has remained largely at the same level since 7/31/2026 because of the following key factors:
1. Mixed Fiscal Q3 2026 Performance and Market Reaction.
Privia Health reported robust revenue for fiscal Q3 2026 (ended September 30, 2026), reaching $657.0 million, which surpassed analysts' consensus estimates of $611.3 million by 7.5%. The company also raised its full-year 2026 revenue guidance to between $2.50 billion and $2.55 billion. However, its Adjusted EPS of $0.21 missed analysts' consensus estimates of $0.24 by 11.8%. This mixed financial performance, particularly the Adjusted EPS miss, led to a 2% decline in the stock price immediately after the earnings release, tempering overall market enthusiasm despite strong revenue growth and an increased full-year outlook.
2. Unfavorable Market Response to Strong Fiscal Q2 2026 Earnings.
Despite a significant beat in fiscal Q2 2026 (ended June 30, 2026) results, Privia Health's stock experienced a notable decline. The company reported actual revenue of $632.63 million, exceeding analysts' expectations of $598.84 million by 5.64%. Additionally, Privia Health announced an EPS of $0.19, substantially topping analysts' consensus estimates of $0.07 by $0.12. Despite these strong financial results, the stock price was down by 8.18% in one day following the announcement, indicating that even positive company-specific news did not translate into sustained upward momentum during the period.
3. Broader Healthcare Sector Headwinds and Valuation Pressure.
The healthcare sector, particularly the physician practice management segment, faced headwinds that contributed to a relatively flat stock trend. The sector experienced a slowdown in deal activity, on track to achieve about half the number of deals in 2026 compared to 2025, influenced by a shifting regulatory landscape and higher interest rates. Concurrently, industry valuation metrics showed a decline, with the median revenue multiple for healthcare from 2025 through fiscal Q3 2026 decreasing by 22% (from 3.6x to 2.8x), and the median EBITDA multiple falling by 21% (from 18.3x to 14.5x), reflecting a more challenging environment for valuations.
4. Future-Oriented Strategic Moves with Limited Immediate Impact.
During the period, Privia Health announced strategic initiatives such as the acquisition of American Choice Healthcare MSSP for approximately $36 million in cash, projected to expand its value-based care attributed lives by over 36,000 beginning in fiscal year 2027. The company also outlined plans to exit its Montana partnership effective January 2027. While these actions are aimed at long-term growth and market expansion, their financial impact is primarily anticipated in fiscal year 2027 and beyond, with minimal expected effects on 2026 results. This forward-looking nature of key strategic developments meant they did not provide an immediate catalyst for significant stock appreciation in the specified period.
Show less
Stock Movement Drivers
Fundamental Drivers
The 1.1% change in PRVA stock from 7/31/2026 to 11/5/2026 was primarily driven by a 23.1% change in the company's Net Income Margin (%).| (LTM values as of) | 7312026 | 11052026 | Change |
|---|---|---|---|
| Stock Price ($) | 23.67 | 23.94 | 1.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,247 | 2,358 | 5.0% |
| Net Income Margin (%) | 1.0% | 1.2% | 23.1% |
| P/E Multiple | 135.0 | 107.4 | -20.5% |
| Shares Outstanding (Mil) | 124 | 126 | -1.6% |
| Cumulative Contribution | 1.1% |
Market Drivers
7/31/2026 to 11/5/2026| Return | Correlation | |
|---|---|---|
| PRVA | 1.1% | |
| Market (SPY) | -1.9% | -10.8% |
| Sector (XLV) | 13.8% | 19.3% |
Fundamental Drivers
The -3.7% change in PRVA stock from 4/30/2026 to 11/5/2026 was primarily driven by a -19.6% change in the company's P/E Multiple.| (LTM values as of) | 4302026 | 11052026 | Change |
|---|---|---|---|
| Stock Price ($) | 24.85 | 23.94 | -3.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,123 | 2,358 | 11.1% |
| Net Income Margin (%) | 1.1% | 1.2% | 10.5% |
| P/E Multiple | 133.6 | 107.4 | -19.6% |
| Shares Outstanding (Mil) | 123 | 126 | -2.3% |
| Cumulative Contribution | -3.7% |
Market Drivers
4/30/2026 to 11/5/2026| Return | Correlation | |
|---|---|---|
| PRVA | -3.7% | |
| Market (SPY) | 2.3% | -9.2% |
| Sector (XLV) | 27.2% | 27.0% |
Fundamental Drivers
The -1.5% change in PRVA stock from 10/31/2025 to 11/5/2026 was primarily driven by a -46.3% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 11052026 | Change |
|---|---|---|---|
| Stock Price ($) | 24.30 | 23.94 | -1.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,900 | 2,358 | 24.1% |
| Net Income Margin (%) | 0.8% | 1.2% | 52.7% |
| P/E Multiple | 200.0 | 107.4 | -46.3% |
| Shares Outstanding (Mil) | 122 | 126 | -3.2% |
| Cumulative Contribution | -1.5% |
Market Drivers
10/31/2025 to 11/5/2026| Return | Correlation | |
|---|---|---|
| PRVA | -1.5% | |
| Market (SPY) | 8.4% | 15.6% |
| Sector (XLV) | 29.8% | 30.3% |
Fundamental Drivers
The 13.9% change in PRVA stock from 10/31/2023 to 11/5/2026 was primarily driven by a 56.5% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312023 | 11052026 | Change |
|---|---|---|---|
| Stock Price ($) | 21.02 | 23.94 | 13.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,507 | 2,358 | 56.5% |
| Net Income Margin (%) | 2.3% | 1.2% | -47.1% |
| P/E Multiple | 71.8 | 107.4 | 49.5% |
| Shares Outstanding (Mil) | 116 | 126 | -7.9% |
| Cumulative Contribution | 13.9% |
Market Drivers
10/31/2023 to 11/5/2026| Return | Correlation | |
|---|---|---|
| PRVA | 13.9% | |
| Market (SPY) | 81.3% | 27.8% |
| Sector (XLV) | 55.5% | 28.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PRVA Return | -26% | -12% | 1% | -15% | 21% | 1% | -31% |
| Peers Return | 11% | -38% | -9% | -78% | -66% | 195% | -86% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 105% |
Monthly Win Rates [3] | |||||||
| PRVA Win Rate | 44% | 50% | 50% | 42% | 58% | 45% | |
| Peers Win Rate | 55% | 47% | 50% | 22% | 33% | 48% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 45% | |
Max Drawdowns [4] | |||||||
| PRVA Max Drawdown | - | -48% | -32% | -32% | -27% | -32% | |
| Peers Max Drawdown | -26% | -57% | -59% | -81% | -87% | -65% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: EVH, AGL, PIII.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/5/2026 (YTD)
How Low Can It Go
| Event | PRVA | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -15.8% | -18.8% |
| % Gain to Breakeven | 18.7% | 23.1% |
| Time to Breakeven | 192 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -23.7% | -9.5% |
| % Gain to Breakeven | 31.1% | 10.5% |
| Time to Breakeven | 973 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -12.4% | -6.7% |
| % Gain to Breakeven | 14.1% | 7.1% |
| Time to Breakeven | 3 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -30.5% | -24.5% |
| % Gain to Breakeven | 44.0% | 32.4% |
| Time to Breakeven | 37 days | 427 days |
In The Past
Privia Health's stock fell -15.8% during the 2025 US Tariff Shock. Such a loss loss requires a 18.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | PRVA | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -23.7% | -9.5% |
| % Gain to Breakeven | 31.1% | 10.5% |
| Time to Breakeven | 973 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -30.5% | -24.5% |
| % Gain to Breakeven | 44.0% | 32.4% |
| Time to Breakeven | 37 days | 427 days |
In The Past
Privia Health's stock fell -15.8% during the 2025 US Tariff Shock. Such a loss loss requires a 18.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Privia Health (PRVA)
Privia Health Group, Inc. (PRVA) is a national physician-enablement company focused on optimizing physician practices and enhancing patient experiences across the United States. The company collaborates with medical groups, health plans, and health systems to empower doctors, both in-person and virtually, while rewarding them for delivering high-quality care. Essentially, Privia aims to support independent providers by streamlining their operations, reducing administrative burdens, and improving their financial viability within the complex healthcare landscape.
To achieve its mission, Privia offers a comprehensive suite of services. This includes providing advanced technology and population health tools designed to enhance provider workflows and patient outcomes. The company also operates as a management services organization (MSO) to alleviate administrative tasks for physicians, allowing them to concentrate more on patient care. Furthermore, Privia establishes single-TIN medical groups to facilitate stronger payer negotiations and align financial incentives, and manages accountable care organizations (ACOs) that drive value-based care through improved patient engagement and quality metrics.
Privia Health's primary customers and partners span various segments of the healthcare industry. These include medical groups, health plans, and health systems seeking to improve operational efficiency and care quality. The company also serves independent providers by offering a robust network that connects them with new patient populations and enables the creation of custom contracts with various purchasers and payers. This integrated approach allows Privia to serve diverse stakeholders, fostering better coordination and alignment of incentives throughout the healthcare continuum.
```AI Analysis | Feedback
Here are 1-3 brief analogies for Privia Health (PRVA):
- Shopify for doctor's offices: Privia provides independent medical practices with the technology, tools, and infrastructure to manage and optimize their operations, much like Shopify empowers small businesses to run online stores.
- Workday for independent physician practices: Privia offers a comprehensive suite of management services, technology, and financial optimization tools to help doctor's offices efficiently handle complex administrative tasks, payer negotiations, and value-based care initiatives, akin to how Workday provides enterprise solutions for HR and finance.
AI Analysis | Feedback
- Technology & Population Health Tools: Provides tools to enhance independent providers' workflows and support population health management.
- Management Services Organization (MSO): Offers administrative support to reduce workload for providers, allowing them to focus on patient care.
- Single-TIN Medical Group: A unified medical group structure that facilitates stronger payer negotiations, clinical integration, and financial alignment for providers.
- Accountable Care Organization (ACO): An ACO focused on driving value-based care by improving patient engagement, reducing inappropriate utilization, and enhancing quality metrics.
- Purchaser & Payer Network: A network that connects providers with new patient populations and helps establish custom contracts with purchasers and payers.
AI Analysis | Feedback
Privia Health (PRVA) sells primarily to other organizations within the healthcare industry, rather than directly to individual consumers. Based on the provided description, its major customers are categories of entities that it collaborates with or provides services to. Specific customer company names are not detailed in the background information, but the types of organizations it serves include:
- Medical Groups, Physician Practices, and Independent Providers: Privia Health works to optimize their practices, enhance workflows through technology and population health tools, and reduce administrative burdens.
- Health Plans and Payers: The company facilitates payer negotiation, helps connect providers with new patient populations, and creates custom contracts for purchasers and payers.
- Health Systems: Privia Health collaborates with health systems to optimize physician practices and enhance patient experiences.
AI Analysis | Feedback
AI Analysis | Feedback
Parth Mehrotra, Chief Executive Officer
Parth Mehrotra was appointed Chief Executive Officer of Privia Health in July 2023, having previously served as President and Chief Operating Officer for over seven years. He is responsible for overseeing the company's growth, financial and operational efficiency across all markets, shared corporate functions, business development efforts, corporate strategy, and technology innovation. Before joining Privia Health, Mr. Mehrotra served as Chief Operating Officer of Brighton Health Group, which was the parent company of Privia Health. His prior experience includes roles as Senior Financial Officer at athenahealth, a member of the Healthcare Investment Banking group at Goldman Sachs, and a management consultant with Accenture. He holds a Bachelor of Arts in Economics from St. Stephen's College, University of Delhi, and an MBA from Northwestern University's Kellogg School of Management.
David Mountcastle, Executive Vice President & Chief Financial Officer
David Mountcastle serves as the Executive Vice President and Chief Financial Officer of Privia Health. He possesses extensive experience in both the healthcare and technology industries, working with companies ranging from startups to large publicly traded corporations. Prior to Privia Health, Mr. Mountcastle was the Chief Financial Officer for Brainware, Inc., which he helped grow to an eventual acquisition by Lexmark International for over $150 million. He also served as Controller/Director of Finance for VT iDirect Technologies, guiding it from a startup phase to a strategic exit for its investors. Earlier in his career, he was the Controller for HealthSpring Inc., which was later sold to United HealthCare, and subsequently became Director of Finance for United HealthCare, where he helped launch a new HMO. Mr. Mountcastle also held the CFO position at Southern Health. He began his career as an auditor at Ernst & Young, LLP. He is a Certified Public Accountant with over 20 years of experience and holds a bachelor's degree in Accounting Information Systems from James Madison University and an MBA with concentrations in Finance and Information Systems from Virginia Commonwealth University.
Chris Voigt, Executive Vice President & Chief Technology Officer
Chris Voigt is the Executive Vice President and Chief Technology Officer of Privia Health. Previously, he held the position of Vice President of Business and Product Development for Privia Health. He brings over 14 years of experience in the healthcare interoperability field, including leading the architecture, design, and construction of public and private health information exchanges (HIEs). Before joining Privia, Mr. Voigt led corporate development for MobileMD, an HIE service provider that was acquired by Siemens in 2011. He also led the U.S. HIE practice for the systems integrator CGI.
Jay Stevens, Chief Growth Officer
Jay Stevens serves as the Chief Growth Officer of Privia Health, where he is responsible for driving physician recruitment, strategy, and revenue growth for Privia Medical Group. He has 20 years of experience in healthcare technology sales and management. Prior to Privia Health, Mr. Stevens was the Senior Vice President of Sales at Kryptiq Corporation, a Surescripts company, where he was responsible for increasing revenue in the independent medical practice, health system, and accountable-care markets. His career also includes various senior sales and management positions at GE Healthcare and IDX Systems.
Greg Kuzma, Executive Vice President & Chief Healthcare Economics Officer
Greg Kuzma is the Executive Vice President and Chief Healthcare Economics Officer at Privia Health, where he leads payer contracting and data analytic functions. He previously held the same role for Brighton Health Group, the former parent company of Privia Health. Mr. Kuzma also operated his own advisory firm, providing services to healthcare clients such as DaVita Healthcare Partners, Apax Partners, and LabCorp. His extensive career as a senior actuarial and operating executive includes experience with companies like Oxford Health Plans, WellCare, Geisinger Health Plan, and MMM, which is the largest Medicare Advantage plan in Puerto Rico.
AI Analysis | Feedback
The key risks to Privia Health's business include:
- Regulatory and Compliance Risks: Privia Health operates in a heavily regulated healthcare industry, and any failure to comply with extensive federal, state, and local governmental laws and regulations could result in significant financial penalties and exclusion from government healthcare programs. These regulations are complex and subject to change, potentially increasing operational costs and restricting business activities. Furthermore, industry consolidation, particularly within the third-party payer sector, could impact Privia Health's ability to negotiate favorable terms and maintain market competitiveness.
- Cybersecurity and Data Privacy Risks: As a technology-driven company that handles sensitive personal health information, Privia Health is highly susceptible to cybersecurity threats, data breaches, and privacy or security incidents. Compliance with complex and changing federal and state privacy and security laws, including HIPAA, is critical, and any breach could have significant financial and reputational impacts.
- Value-Based Care (VBC) Risks: Privia Health is exposed to risks associated with its value-based care arrangements, where payments are tied to specific targets for the cost and quality of care. Changes in these arrangements or a failure to meet performance standards could negatively impact the company's revenues and financial condition.
AI Analysis | Feedback
AI Analysis | Feedback
Privia Health (NASDAQ: PRVA) operates in several significant addressable markets within the healthcare sector, primarily in the U.S.
-
Physician Enablement Market: The total addressable market for physician enablement is estimated to be approximately US$1.9 trillion in the U.S. and is expected to grow at a CAGR of over 6% annually, reaching US$3.5 trillion by 2030.
-
Value-Based Healthcare Service Market: The U.S. value-based healthcare service market was valued at an estimated US$4.01 trillion in 2024. This market is projected to grow at a compound annual growth rate (CAGR) of 7.4% from 2025 to 2030, reaching US$6.16 trillion by 2030.
-
Practice Management Systems Market: The U.S. practice management system market size was approximately US$6.65 billion in 2025. It is projected to reach around US$16.38 billion by 2035, growing at a CAGR of 9.43% during the forecast period from 2026 to 2035.
-
Accountable Care Solutions Market: The global accountable care solutions market was valued at US$24.95 billion in 2025 and is projected to reach US$69.91 billion by 2034, exhibiting a CAGR of 11.52% from 2026-2034. North America currently holds the largest share of this market, accounting for over 52.0% in 2024.
AI Analysis | Feedback
Privia Health Group, Inc. (PRVA) is expected to drive future revenue growth over the next 2-3 years through several key strategies:
- Growth in Implemented Providers: Privia Health consistently focuses on increasing its network of implemented providers. The company's guidance anticipates reaching between 5,900 and 6,000 implemented providers by the end of 2026, up from 5,380 at the end of 2025. This expansion directly contributes to higher practice collections and overall revenue.
- Expansion of Value-Based Care (VBC) Attributed Lives: A core component of Privia Health's strategy is its commitment to value-based care arrangements. The acquisition of the Accountable Care Organization (ACO) business from Evolent Health, completed in late 2025, significantly boosted the number of attributed lives in VBC arrangements, reaching approximately 1.5 million. This expansion in VBC attributed lives across commercial, Medicare, Medicare Advantage, and Medicaid programs is expected to positively contribute to Adjusted EBITDA in 2026 and beyond.
- Geographic Market Expansion: Privia Health is actively expanding its national footprint into new states and markets. For instance, the company recently expanded into Arizona in April 2025, partnering with a multi-specialty group. This strategic geographic expansion increases the potential pool of providers and patients, thereby driving revenue growth.
- Strategic Technology Integration and Partnerships: The company continues to leverage its technology and population health tools to optimize physician practices and enhance workflows. Recent partnerships with AI-based tech enablers like Navina (an AI-powered primary care platform) and Calm Waters AI (an AI Evaluation & Management coding application) aim to improve efficiency, clinical decision support, and patient engagement. These technological advancements are expected to enhance performance in value-based care models and strengthen provider retention, indirectly contributing to revenue growth.
AI Analysis | Feedback
Share Issuance
- Privia Health's Initial Public Offering (IPO) closed on May 3, 2021, with 22,425,000 shares of common stock issued at $23.00 per share.
- The company itself offered 5,725,000 shares in the IPO, generating approximately $131.7 million in gross proceeds.
- EVP & CFO David Mountcastle received equity awards of 42,584 and 35,335 shares of common stock at a price of $0.00 per share as compensation grants in March 2026, stemming from restricted stock units and performance stock units from 2021 and 2023.
Outbound Investments
- Privia Health deployed approximately $180 million for strategic acquisitions in 2025.
- This capital was used to acquire Evelyn Health's ACO business in December 2025, adding over 120,000 value-based attributed lives.
- The company also entered the Arizona market in April 2025 through its acquisition of IMS.
Capital Expenditures
- Privia Health reported "de minimis capital expenditures" for the full year 2025.
- In Q4 2023, capital expenditures were $23K, an increase of 27.8% from the prior quarter, used for funding long-term assets and infrastructure.
- For 2026, the company anticipates "minimum capital expenditures" and expects to end the year with approximately $600 million in cash, assuming no new business development.
Peer Outperformance in Health Care Services
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| PRVA | Privia Health | 16.2% | 107.4x | -4.3% | 6.1% | -12.9% | — |
| RDNT | RadNet | 14.1% | -287.4x | -0.2% | 173.3% | 125.5% | +138pp |
| CI | Cigna | 15.1% | 12.4x | 18.8% | 4.1% | 54.5% | +67pp |
| ADUS | Addus HomeCare | 13.5% | 20.9x | 5.8% | 49.5% | 24.3% | +37pp |
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 7.6% | 56.6% | 93.6% | CAH 498% · MCK 396% · COR 181% |
| Health Care Services ← | 20 | 33.8% | 28.8% | 6.1% | HIMS 189% · RDNT 125% · DGX 100% |
| Health Care Facilities | 25 | 13.9% | 27.4% | -1.4% | THC 280% · NHC 210% · EHC 186% |
| Managed Health Care | 8 | 47.9% | 1.6% | -2.2% | OSCR 95% · HQY 52% · ELV 10% |
| Health Care Equipment | 50 | 11.0% | 17.8% | -17.6% | UFPT 355% · GKOS 286% · PLSE 127% |
| Pharmaceuticals | 61 | -12.9% | 10.6% | -37.3% | LQDA 977% · XERS 571% · KNSA 500% |
| Health Care Supplies | 11 | 23.9% | 17.0% | -40.1% | LNTH 248% · HAE 66% · MMSI 29% |
| Life Sciences Tools & Services | 108 | -8.1% | -18.9% | -74.5% | AXGN 255% · NTRA 214% · MEDP 181% |
| Biotechnology | 364 | -25.8% | -36.1% | -82.0% | ELVN 1073% · TRVI 995% · DNTH 956% |
| Health Care Technology | 21 | -21.4% | -50.4% | -82.8% | VEEV -3% · DOCS -51% |
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 14.24 |
| Mkt Cap | 1.2 |
| Rev LTM | 2,350 |
| Op Inc LTM | -82 |
| FCF LTM | 6 |
| FCF 3Y Avg | -40 |
| CFO LTM | 30 |
| CFO 3Y Avg | -8 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.4% |
| Rev Chg 3Y Avg | 14.0% |
| Rev Chg Q | 15.0% |
| QoQ Delta Rev Chg LTM | 3.5% |
| Op Inc Chg LTM | 60.2% |
| Op Inc Chg 3Y Avg | -22.8% |
| Op Mgn LTM | -2.0% |
| Op Mgn 3Y Avg | -2.9% |
| QoQ Delta Op Mgn LTM | 1.5% |
| CFO/Rev LTM | 1.3% |
| CFO/Rev 3Y Avg | 0.5% |
| FCF/Rev LTM | 0.6% |
| FCF/Rev 3Y Avg | -0.5% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Care for its patients’ needs | 2,123 | 1,736 | 1,658 | 1,357 | |
| Capitated revenue | 0 | ||||
| Care management fees (per member per month (PMPM)) | 37 | ||||
| Fee-for-service (FFS)-administrative services | 69 | ||||
| Fee-for-service (FFS)-patient care | 772 | ||||
| Other revenue | 5 | ||||
| Shared savings | 83 | ||||
| Total | 2,123 | 1,736 | 1,658 | 1,357 | 966 |
Price Behavior
| Market Price | $23.94 | |
| Market Cap ($ Bil) | 3.0 | |
| First Trading Date | 04/29/2021 | |
| Distance from 52W High | -14.8% | |
| 50 Days | 200 Days | |
| DMA Price | $20.97 | $22.64 |
| DMA Trend | down | down |
| Distance from DMA | 14.2% | 5.7% |
| 3M | 1YR | |
| Volatility | 27.9% | 32.9% |
| Downside Capture | 54.25 | 82.96 |
| Upside Capture | 55.74 | 58.89 |
| Correlation (S&P 500) | 19.9% | 24.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.56 | 0.20 | 0.35 | 0.03 | 0.57 | 0.74 |
| Up Beta | -4.02 | -2.55 | -0.74 | -0.14 | 0.37 | 0.77 |
| Down Beta | 1.33 | 0.82 | 0.26 | 0.04 | 0.27 | 0.21 |
| Up Capture | 131% | 57% | 37% | -8% | 51% | 71% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 13 | 23 | 30 | 58 | 115 | 365 |
| Down Capture | -16% | 16% | 100% | 34% | 92% | 103% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 9 | 20 | 33 | 66 | 130 | 375 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PRVA | |
|---|---|---|---|---|
| PRVA | -3.0% | 32.9% | -0.07 | - |
| Sector ETF (XLV) | 29.2% | 16.9% | 1.33 | 30.4% |
| Equity (SPY) | 9.5% | 13.6% | 0.41 | 15.6% |
| Gold (GLD) | 3.6% | 28.7% | 0.11 | 3.5% |
| Commodities (DBC) | 37.7% | 21.2% | 1.40 | -20.2% |
| Real Estate (VNQ) | 12.0% | 14.2% | 0.55 | 33.3% |
| Bitcoin (BTCUSD) | -20.8% | 43.3% | -0.42 | 16.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PRVA | |
|---|---|---|---|---|
| PRVA | -0.8% | 46.6% | 0.13 | - |
| Sector ETF (XLV) | 8.6% | 15.4% | 0.36 | 33.2% |
| Equity (SPY) | 11.3% | 17.3% | 0.48 | 36.1% |
| Gold (GLD) | 17.5% | 19.1% | 0.74 | 3.8% |
| Commodities (DBC) | 8.0% | 19.6% | 0.29 | 1.0% |
| Real Estate (VNQ) | 1.2% | 18.9% | -0.05 | 37.7% |
| Bitcoin (BTCUSD) | 5.9% | 51.5% | 0.29 | 25.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PRVA | |
|---|---|---|---|---|
| PRVA | -3.7% | 48.5% | 0.03 | - |
| Sector ETF (XLV) | 12.2% | 16.8% | 0.60 | 30.7% |
| Equity (SPY) | 14.9% | 18.0% | 0.70 | 32.7% |
| Gold (GLD) | 12.0% | 16.5% | 0.59 | 2.8% |
| Commodities (DBC) | 7.6% | 18.1% | 0.33 | 1.7% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.23 | 33.9% |
| Bitcoin (BTCUSD) | 61.3% | 66.2% | 1.01 | 20.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 11/5/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/6/2026 | -8.2% | -10.1% | -13.7% |
| 5/7/2026 | 0.0% | -5.7% | -9.8% |
| 2/26/2026 | 10.0% | 7.3% | -10.9% |
| 11/6/2025 | -4.2% | -3.2% | -5.6% |
| 8/7/2025 | -1.4% | 6.3% | 17.7% |
| 5/8/2025 | 7.5% | 4.2% | -0.6% |
| 2/27/2025 | 5.8% | 6.8% | -4.7% |
| 11/7/2024 | 6.5% | 3.2% | 0.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 14 | 13 | 9 |
| # Negative | 8 | 9 | 13 |
| Median Positive | 7.0% | 6.3% | 8.2% |
| Median Negative | -4.2% | -5.7% | -9.1% |
| Max Positive | 14.3% | 19.1% | 44.2% |
| Max Negative | -8.2% | -14.8% | -20.3% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/6/2026 | -8.2% | -10.1% | -13.7% |
| 5/7/2026 | 0.0% | -5.7% | -9.8% |
| 2/26/2026 | 10.0% | 7.3% | -10.9% |
| 11/6/2025 | -4.2% | -3.2% | -5.6% |
| 8/7/2025 | -1.4% | 6.3% | 17.7% |
| 5/8/2025 | 7.5% | 4.2% | -0.6% |
| 2/27/2025 | 5.8% | 6.8% | -4.7% |
| 11/7/2024 | 6.5% | 3.2% | 0.1% |
| 8/8/2024 | 5.9% | 5.5% | 2.1% |
| 5/9/2024 | -4.4% | -7.9% | -9.1% |
| 2/27/2024 | 9.7% | 9.4% | -5.2% |
| 11/3/2023 | 14.3% | 6.3% | 8.2% |
| 8/3/2023 | -1.7% | -1.1% | -2.5% |
| 5/4/2023 | 1.2% | 2.4% | -8.3% |
| 2/28/2023 | 3.4% | 4.9% | 1.7% |
| 11/10/2022 | 11.9% | -6.0% | -9.7% |
| 8/11/2022 | 4.0% | -1.4% | 13.3% |
| 5/12/2022 | 10.6% | 19.1% | 41.0% |
| 3/22/2022 | -1.9% | 7.9% | 4.8% |
| 11/8/2021 | 14.3% | 18.3% | -20.3% |
| 8/9/2021 | -4.8% | -14.8% | -18.6% |
| 5/27/2021 | -4.2% | -2.7% | 44.2% |
| SUMMARY STATS | |||
| # Positive | 14 | 13 | 9 |
| # Negative | 8 | 9 | 13 |
| Median Positive | 7.0% | 6.3% | 8.2% |
| Median Negative | -4.2% | -5.7% | -9.1% |
| Max Positive | 14.3% | 19.1% | 44.2% |
| Max Negative | -8.2% | -14.8% | -20.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 02/27/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 02/27/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 03/25/2022 | 10-K |
| 09/30/2021 | 11/08/2021 | 10-Q |
| 06/30/2021 | 08/09/2021 | 10-Q |
| 03/31/2021 | 05/28/2021 | 10-Q |
| 12/31/2020 | 04/30/2021 | 424B4 |
Recent Forward Guidance
Updated 11/5/2026Latest: Q3 2026 Earnings Reported 11/5/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Practice Collections | Reported | 3.90 Bil | 3.92 Bil | 3.95 Bil | 6.1% | Raised | Guidance: 3.70 Bil for 2026 | |
| 2026 Care Margin | Reported | 5.35E10% | 5.375E10% | 5.4E10% | 2.9% | Raised | Guidance: 5.225E10% for 2026 | |
| 2026 Platform Contribution | Reported | 280.00 Mil | 282.50 Mil | 285.00 Mil | 6.6% | Raised | Guidance: 265.00 Mil for 2026 | |
| 2026 Attributed Lives | Reported | 1.68 Mil | 1.68 Mil | 1.69 Mil | 2.7% | Raised | Guidance: 1.64 Mil for 2026 | |
| 2026 Implemented Providers | Reported | 6000 | 0.8% | Raised | Guidance: 5950 for 2026 | |||
| 2026 Cash and Cash Equivalents | Reported | 520.00 Mil | 520.00 Mil | |||||
| 2026 Revenue | Reported | 2.50 Bil | 2.52 Bil | 2.55 Bil | 5.2% | Raised | Guidance: 2.40 Bil for 2026 | |
| 2026 Adjusted EBITDA | Reported | 154.00 Mil | 155.50 Mil | 157.00 Mil | 3.7% | Raised | Guidance: 150.00 Mil for 2026 | |
| 2026 Adjusted EBITDA to Free Cash Flow Conversion Rate | Reported | 0.7 | ||||||
| 2026 Free Cash Flow | Reported | 107.80 Mil | 108.85 Mil | 109.90 Mil | ||||
Prior: Q2 2026 Earnings Reported 8/6/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Implemented Providers | Reported | 5900 | 5950 | 0 | Affirmed | Guidance: 5950 for 2026 | ||
| 2026 Attributed Lives | Reported | 1.62 Mil | 1.64 Mil | 1.6% | Raised | Guidance: 1.61 Mil for 2026 | ||
| 2026 Practice Collections | Reported | 3.65 Bil | 3.70 Bil | 0 | Affirmed | Guidance: 3.70 Bil for 2026 | ||
| 2026 Care Margin | Reported | 5.15E10% | 5.225E10% | 0 | Affirmed | Guidance: 5.225E10% for 2026 | ||
| 2026 Platform Contribution | Reported | 260.00 Mil | 265.00 Mil | 0 | Affirmed | Guidance: 265.00 Mil for 2026 | ||
| 2026 GAAP Revenue | Reported | 2.35 Bil | 2.40 Bil | 0 | Affirmed | Guidance: 2.40 Bil for 2026 | ||
| 2026 Adjusted EBITDA | Reported | 145.00 Mil | 150.00 Mil | 0 | Affirmed | Guidance: 150.00 Mil for 2026 | ||
Q1 2026 Earnings Reported 5/7/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Implemented Providers | Reported | 5900 | 5950 | 6000 | 0 | Affirmed | Guidance: 5950 for 2026 | |
| 2026 Attributed Lives | Reported | 1.60 Mil | 1.61 Mil | 1.62 Mil | 2.4% | Raised | Guidance: 1.57 Mil for 2026 | |
| 2026 Practice Collections | Reported | 3.65 Bil | 3.70 Bil | 3.75 Bil | 0 | Affirmed | Guidance: 3.70 Bil for 2026 | |
| 2026 Care Margin | Reported | 5.15E10% | 5.225E10% | 5.3E10% | 0 | Affirmed | Guidance: 5.225E10% for 2026 | |
| 2026 Platform Contribution | Reported | 260.00 Mil | 265.00 Mil | 270.00 Mil | 0 | Affirmed | Guidance: 265.00 Mil for 2026 | |
| 2026 Revenue | Reported | 2.35 Bil | 2.40 Bil | 2.45 Bil | 0 | Affirmed | Guidance: 2.40 Bil for 2026 | |
| 2026 Adjusted EBITDA | Reported | 145.00 Mil | 150.00 Mil | 155.00 Mil | 0 | Affirmed | Guidance: 150.00 Mil for 2026 | |
Q4 2025 Earnings Reported 2/26/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Implemented Providers | Reported | 5900 | 5950 | 6000 | 11.7% | Higher New | Guidance: 5325 for 2025 | |
| 2026 Attributed Lives | Reported | 1.55 Mil | 1.57 Mil | 1.60 Mil | 11.5% | Higher New | Guidance: 1.41 Mil for 2025 | |
| 2026 Practice Collections | Reported | 3.65 Bil | 3.70 Bil | 3.75 Bil | 6.5% | Higher New | Guidance: 3.48 Bil for 2025 | |
| 2026 Care Margin | Reported | 5.15E10% | 5.225E10% | 5.3E10% | 14.2% | Higher New | Guidance: 4.575E10% for 2025 | |
| 2026 Platform Contribution | Reported | 260.00 Mil | 265.00 Mil | 270.00 Mil | 14.0% | Higher New | Guidance: 232.50 Mil for 2025 | |
| 2026 Revenue | Reported | 2.35 Bil | 2.40 Bil | 2.45 Bil | 15.7% | Higher New | Guidance: 2.08 Bil for 2025 | |
| 2026 Adjusted EBITDA | Reported | 145.00 Mil | 150.00 Mil | 155.00 Mil | 25.5% | Higher New | Guidance: 119.50 Mil for 2025 | |
Insider Activity
Updated 9/3/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Mountcastle, David | EVP & Chief Financial Officer | Direct | Sell | 7132026 | 27.67 | 21,275 | 588,679 | 4,561,483 | Form |
| 2 | Mountcastle, David | EVP & Chief Financial Officer | Direct | Sell | 7092026 | 27.57 | 600 | 16,542 | 5,131,549 | Form |
| 3 | Morris, Matthew Shawn | Direct | Sell | 7072026 | 27.24 | 53,722 | 1,463,387 | 1,857,441 | Form | |
| 4 | Morris, Matthew Shawn | Direct | Sell | 7072026 | 27.33 | 59,037 | 1,613,481 | 2,094,872 | Form | |
| 5 | Mountcastle, David | EVP & Chief Financial Officer | Direct | Sell | 7072026 | 27.50 | 24,734 | 680,185 | 5,135,020 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Mountcastle, David | EVP & Chief Financial Officer | Direct | Sell | 7132026 | 27.67 | 21,275 | 588,679 | 4,561,483 | Form |
| 2 | Mountcastle, David | EVP & Chief Financial Officer | Direct | Sell | 7092026 | 27.57 | 600 | 16,542 | 5,131,549 | Form |
| 3 | Morris, Matthew Shawn | Direct | Sell | 7072026 | 27.24 | 53,722 | 1,463,387 | 1,857,441 | Form | |
| 4 | Morris, Matthew Shawn | Direct | Sell | 7072026 | 27.33 | 59,037 | 1,613,481 | 2,094,872 | Form | |
| 5 | Mountcastle, David | EVP & Chief Financial Officer | Direct | Sell | 7072026 | 27.50 | 24,734 | 680,185 | 5,135,020 | Form |
| 6 | Morris, Matthew Shawn | Direct | Sell | 7022026 | 26.70 | 82,675 | 2,207,728 | 2,046,865 | Form | |
| 7 | Morris, Matthew Shawn | Direct | Sell | 7022026 | 25.72 | 52,823 | 1,358,608 | 1,971,464 | Form | |
| 8 | Morris, Matthew Shawn | Direct | Sell | 6302026 | 25.33 | 63,212 | 1,601,160 | 1,941,570 | Form | |
| 9 | Morris, Matthew Shawn | Direct | Sell | 6302026 | 25.33 | 88,110 | 2,231,826 | 1,941,570 | Form | |
| 10 | Mountcastle, David | EVP & Chief Financial Officer | Direct | Sell | 6302026 | 25.18 | 17,196 | 432,995 | 5,324,613 | Form |
| 11 | Mehrotra, Parth | Chief Executive Officer | Direct | Sell | 5132026 | 22.64 | 15,647 | 354,248 | 9,833,842 | Form |
| 12 | Mountcastle, David | EVP & Chief Financial Officer | Direct | Sell | 5132026 | 22.60 | 3,385 | 76,501 | 4,779,041 | Form |
| 13 | Mehrotra, Parth | Chief Executive Officer | Direct | Sell | 5132026 | 22.55 | 105,439 | 2,377,649 | 10,147,590 | Form |
| 14 | Mountcastle, David | EVP & Chief Financial Officer | Direct | Sell | 5052026 | 25.00 | 1,206 | 30,150 | 5,371,175 | Form |
| 15 | Morris, Matthew Shawn | Direct | Sell | 5052026 | 24.96 | 1,017 | 25,384 | 1,701,972 | Form | |
| 16 | Mountcastle, David | EVP & Chief Financial Officer | Direct | Sell | 5052026 | 25.03 | 7,179 | 179,690 | 5,377,620 | Form |
| 17 | Morris, Matthew Shawn | Direct | Sell | 5052026 | 24.99 | 17,096 | 427,229 | 1,704,018 | Form | |
| 18 | Mountcastle, David | EVP & Chief Financial Officer | Direct | Sell | 4062026 | 20.85 | 5,566 | 116,051 | 4,479,560 | Form |
| 19 | Mountcastle, David | EVP & Chief Financial Officer | Direct | Sell | 3182026 | 22.11 | 6,391 | 141,305 | 4,873,331 | Form |
| 20 | Mehrotra, Parth | Chief Executive Officer | Direct | Sell | 3182026 | 22.11 | 26,509 | 586,114 | 12,280,845 | Form |
| 21 | Mountcastle, David | EVP & Chief Financial Officer | Direct | Sell | 3162026 | 21.52 | 6,565 | 141,279 | 4,880,822 | Form |
| 22 | Mehrotra, Parth | Chief Executive Officer | Direct | Sell | 3162026 | 21.52 | 27,229 | 585,968 | 12,523,607 | Form |
| 23 | Mountcastle, David | EVP & Chief Financial Officer | Direct | Sell | 3162026 | 21.90 | 6,453 | 141,321 | 5,110,781 | Form |
| 24 | Mehrotra, Parth | Chief Executive Officer | Direct | Sell | 3162026 | 21.90 | 26,763 | 586,110 | 13,341,064 | Form |
| 25 | Mehrotra, Parth | Chief Executive Officer | Direct | Sell | 3122026 | 22.71 | 21,097 | 479,113 | 7,328,472 | Form |
| 26 | Mehrotra, Parth | Chief Executive Officer | Direct | Sell | 3102026 | 22.86 | 41,999 | 959,903 | 7,857,566 | Form |
| 27 | Fargis, Edward C | EVP & General Counsel | Direct | Sell | 3102026 | 22.84 | 4,949 | 113,035 | 1,911,959 | Form |
| 28 | Mountcastle, David | EVP & Chief Financial Officer | Direct | Sell | 3102026 | 22.84 | 5,829 | 133,134 | 3,697,865 | Form |
| 29 | Mehrotra, Parth | Chief Executive Officer | Direct | Sell | 3102026 | 23.15 | 21,440 | 496,336 | 8,931,131 | Form |
| 30 | Fargis, Edward C | EVP & General Counsel | Direct | Sell | 3102026 | 23.15 | 4,394 | 101,721 | 2,052,479 | Form |
| 31 | Mountcastle, David | EVP & Chief Financial Officer | Direct | Sell | 3102026 | 23.15 | 5,177 | 119,848 | 3,882,996 | Form |
| 32 | Mountcastle, David | EVP & Chief Financial Officer | Direct | Sell | 3022026 | 25.05 | 7,697 | 192,810 | 4,331,370 | Form |
| 33 | Morris, Matthew Shawn | Direct | Sell | 3022026 | 25.00 | 16,550 | 413,750 | 1,704,700 | Form | |
| 34 | Mountcastle, David | EVP & Chief Financial Officer | Direct | Sell | 3022026 | 25.00 | 5,361 | 134,025 | 4,322,725 | Form |
| 35 | Morris, Matthew Shawn | Direct | Sell | 3022026 | 24.99 | 7,788 | 194,622 | 1,704,018 | Form | |
| 36 | Morris, Matthew Shawn | Direct | Sell | 12162025 | 25.01 | 13,647 | 341,311 | 1,705,382 | Form | |
| 37 | Mountcastle, David | EVP & Chief Financial Officer | Direct | Sell | 12162025 | 25.03 | 23,887 | 597,892 | 4,327,912 | Form |
Investor Activity (13F)
Updated Nov 6, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Health Care Services Resources |
| HealthLeaders Media |
| Medical Economics |
| Physicians Practice |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.